Levosulpiride in somatoform disorders: A double-blind, placebo-controlled cross-over study
| Autor: | N Rudas, Ac Altamura, A. Ermentini, Rosaria Pioli, Gian Paolo Guaraldi, A. E. Di Rosa, G. Invernizzi, G. Tacchini |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.drug_class Placebo Levosulpiride Crossover study somatoform disorders somatoform disorder schedule pharmacotherapy levosulpiride Psychiatry and Mental health chemistry.chemical_compound Pharmacotherapy medicine.anatomical_structure chemistry Tolerability Anticholinergic Extrapyramidal system Medicine business Psychiatry Psychopathology |
| Zdroj: | International Journal of Psychiatry in Clinical Practice. 7:155-159 |
| ISSN: | 1471-1788 1365-1501 |
| DOI: | 10.1080/13651500310001833 |
| Popis: | Reliable data on the psychopharmacotherapy of somatoform disorders (SDs) are scanty because of patients' poor psychopathological awareness and compliance, the need for combination treatment, and the lack of suitable instruments for clinical diagnosis and assessment. The aim of the present study was to investigate the efficacy and tolerability of low doses of levosulpiride in the treatment of SDs. Seventy-four patients with SDs diagnosed according to ICD-10 and DSM-IIIR criteria by means of the Comprehensive International Schedule for Somatoform Disorders-Somatoform Disorders Schedule (CISSD-SDS) were treated for 4 weeks either with levosulpiride (50 mg b.i.d.) or placebo, under double-blind, cross-over conditions. The clinical evaluation was performed using CISSD-SDS. Side-effects were evaluated using the Simpson and Angus Extrapyramidal Side Effects Scale (EPSE) and specific check-lists for anticholinergic and endocrine side effects. Levosulpiride significantly reduced the number of SD symptoms compared to placebo ( P =0.007) after 4 weeks of treatment. Eighty per cent of positive responses were observed during treatment with levosulpiride in the placebo-levosulpiride sequence; on the other hand, only 44% of positive responses were found during treatment with active compound in the levosulpiride-placebo sequence ( P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|